3D pharmacophore-based discovery of novel Kv10.1 inhibitors with antiproliferative activity

(1) Background: The voltage-gated potassium channel K$_V$10.1 (Eag1) is considered a near- universal tumour marker and represents a promising new target for the discovery of novel anticancer drugs. (2) Methods: We utilized the ligand-based drug discovery methodology using 3D pharmacophore modelling and medicinal chemistry approaches to prepare a novel structural class of K$_V$10.1 inhibitors. Whole-cell patch clamp experiments were used to investigate potency, selectivity, kinetics and mode of inhibition. Anticancer activity was determined using 2D and 3D cell-based models. (3) Results: The virtual screening hit compound ZVS-08 discovered by 3D pharmacophore modelling exhibited an IC$_{50}$ value of 3.70 µM against K$_V$10.1 and inhibited the channel in a voltagedependent manner consistent with the action of a gating modifier. Structural optimization resulted in the most potent K$_V$10.1 inhibitor of the series with an IC$_{50}$ value of 740 nM, which was potent on the MCF-7 cell line expressing high K$_V$10.1 levels and low hERG levels, induced significant apoptosis in tumour spheroids of Colo-357 cells and was not mutagenic. (4) Conclusions: Computational ligand-based drug design methods can be successful in the discovery of new potent K$_V$10.1 inhibitors. The main problem in the field of K$_V$10.1 inhibitors remains selectivity against the hERG channel, which needs to be addressed in the future also with target-based drug design methods